Took an unusual biotech/healthcare position today. Credit to @tradewithcong for the idea to long this one. ZTS is best described as an animal biotech/pharmacy. They develop, manufactures and sells pet + livestock medicines, vaccines, diagnostics and related technologies. Four members of congress bought ZTS in the last 60 days + @michaeljburry has bought in May and August of 2026 as well. They have suffered from a decline in companion pet spending like many other pet companies...however, the extent of share decline may not be justified revenue as they also treat livestock both internationally and domestically. In addition to various dermatological and degenerative treatments, ZTS has a screwworm (parasite) treatment/eradicant which notably has an FDA EUA for a canine screwworm treatment. They have free-cash-flow w/1H26 operating cash flow of $1.06B, a clean balance sheet, high historical returns, and a low float due to recent debt-funded repurchases which would magnify per-share recovery if operating profit stabilizes. Worth a punt give the fact its been consolidating in its current range for a while with a weekly bull divergence. Let's see. 🍌(CryptoCondom)